{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:18:13Z","timestamp":1788848293350,"version":"build-2803163510"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["Lo 1853\/1-2"],"award-info":[{"award-number":["Lo 1853\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005690","name":"Saarland University","doi-asserted-by":"publisher","award":["HOMFOR"],"award-info":[{"award-number":["HOMFOR"]}],"id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005690","name":"Saarland University","doi-asserted-by":"publisher","award":["start-up promotion"],"award-info":[{"award-number":["start-up promotion"]}],"id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005690","name":"Saarland University","doi-asserted-by":"publisher","award":["Young Investigator Grant"],"award-info":[{"award-number":["Young Investigator Grant"]}],"id":[{"id":"10.13039\/501100005690","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human IgA Abs engage neutrophils for cancer immunotherapy more effectively than IgG Abs. Previous studies demonstrated that engineering approaches improved biochemical and functional properties. In this study, we report a novel, to our knowledge, IgA2 Ab against the epidermal growth factor receptor generated by protein engineering and polymerization. The resulting molecule demonstrated a covalent linkage of L and H chains and an effective polymerization by the joining chain. The engineered dimer outperformed its monomeric variant in functional experiments on Fab-mediated modes of action and binding to the Fc receptor. The capacity to engage neutrophils for Ab-dependent cell-mediated cytotoxicity (ADCC) of adherent growing target cancer cells was cell line dependent. Although the engineered dimer displayed a long-term efficacy against the vulva carcinoma cell line A431, there was a notable in-efficacy against human papillomavirus (HPV)\u2212 head and neck squamous cell carcinoma (HNSCC) cell lines. However, the highly engineered IgA Abs triggered a neutrophil-mediated cytotoxicity against HPV+ HNSCC cell lines. Short-term ADCC efficacy correlated with the target cells\u2019 epidermal growth factor receptor expression and the ability of cancer cell\u2013conditioned media to enhance the CD147 surface level on neutrophils. Notably, the HPV+ HNSCC cell lines demonstrated a significant increment in releasing soluble CD147 and a reduced induction of membranous CD147 on neutrophils compared with HPV\u2212 cells. Although membranous CD147 on neutrophils may impair proper IgA\u2013Fc receptor binding, soluble CD147 enhanced the IgA\u2013neutrophil-mediated ADCC in a dose-dependent manner. Thus, engineering IgA Abs and impedance-based ADCC assays provided valuable information regarding the target\u2013effector cell interaction and identified CD147 as a putative critical parameter for neutrophil-mediated cytotoxicity.<\/jats:p>","DOI":"10.4049\/jimmunol.2300544","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:26:34Z","timestamp":1716557194000},"page":"148-160","source":"Crossref","is-referenced-by-count":4,"title":["Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells"],"prefix":"10.1093","volume":"213","author":[{"given":"Anabel","family":"Zwick","sequence":"first","affiliation":[{"name":"Institute of Virology, Saarland University Medical Center , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4360-0935","authenticated-orcid":false,"given":"Felix Leon","family":"Braun","sequence":"additional","affiliation":[{"name":"Institute of Virology, Saarland University Medical Center , Homburg ,","place":["Germany"]},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery; Saarland University Medical Center , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5547-0116","authenticated-orcid":false,"given":"Lennert Jochen","family":"Weber","sequence":"additional","affiliation":[{"name":"Institute of Virology, Saarland University Medical Center , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4614-7000","authenticated-orcid":false,"given":"Manuel","family":"Linder","sequence":"additional","affiliation":[{"name":"Institute of Virology, Saarland University Medical Center , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-9282","authenticated-orcid":false,"given":"Maximilian","family":"Linxweiler","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Head and Neck Surgery; Saarland University Medical Center , Homburg\/Saar ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2529-1900","authenticated-orcid":false,"given":"Stefan","family":"Lohse","sequence":"additional","affiliation":[{"name":"Institute of Virology, Saarland University Medical Center , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"2025012305113520200_r1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"2025012305113520200_r2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"2025012305113520200_r3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.it.2019.04.012","article-title":"Neutrophil diversity in health and disease","volume":"40","author":"Silvestre-Roig","year":"2019","journal-title":"Trends Immunol."},{"key":"2025012305113520200_r4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"2025012305113520200_r5","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1158\/0008-5472.CAN-19-1972","article-title":"Circulating tumor cell-neutrophil tango along the metastatic process","volume":"79","author":"Saini","year":"2019","journal-title":"Cancer Res."},{"key":"2025012305113520200_r6","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1007\/s13277-015-4349-3","article-title":"Circulating tumor-associated neutrophils (cTAN) contribute to circulating tumor cell survival by suppressing peripheral leukocyte activation","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumour Biol."},{"key":"2025012305113520200_r7","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1038\/s41467-022-34407-1","article-title":"Connecting multiple microenvironment proteomes uncovers the biology in head and neck cancer","volume":"13","author":"Busso-Lopes","year":"2022","journal-title":"Nat. Commun."},{"key":"2025012305113520200_r8","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/hed.25737","article-title":"Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer","volume":"41","author":"Yasumatsu","year":"2019","journal-title":"Head Neck"},{"key":"2025012305113520200_r9","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/hed.25583","article-title":"High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: systematic review and meta-analysis","volume":"41","author":"Yang","year":"2019","journal-title":"Head Neck"},{"key":"2025012305113520200_r10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol."},{"key":"2025012305113520200_r11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","article-title":"Advances in antibody-based therapy in oncology","volume":"4","author":"Zinn","year":"2023","journal-title":"Nat. Cancer"},{"key":"2025012305113520200_r12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41568-022-00531-9","article-title":"Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment","volume":"23","author":"Ruffin","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"2025012305113520200_r13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3389\/fonc.2019.00383","article-title":"Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma","volume":"9","author":"Taberna","year":"2019","journal-title":"Front. Oncol."},{"key":"2025012305113520200_r14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"key":"2025012305113520200_r15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mds291","article-title":"Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial","volume":"24","author":"Mes\u00eda","year":"2013","journal-title":"Ann. Oncol."},{"key":"2025012305113520200_r16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2025012305113520200_r17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","article-title":"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol."},{"key":"2025012305113520200_r18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"2025012305113520200_r19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"2025012305113520200_r20","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat. Med."},{"key":"2025012305113520200_r21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fimmu.2019.00553","article-title":"IgA and Fc\u03b1RI: pathological roles and therapeutic opportunities","volume":"10","author":"Breedveld","year":"2019","journal-title":"Front. Immunol."},{"key":"2025012305113520200_r22","doi-asserted-by":"crossref","first-page":"101581","DOI":"10.1016\/j.smim.2021.101581","article-title":"Therapeutic exploitation of neutrophils to fight cancer","volume":"57","author":"Gruijs","year":"2021","journal-title":"Semin. Immunol."},{"key":"2025012305113520200_r23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjh.14624","article-title":"Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity","volume":"181","author":"Lohse","year":"2018","journal-title":"Br. J. Haematol."},{"key":"2025012305113520200_r24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/0008-5472.CAN-15-1232","article-title":"An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo","volume":"76","author":"Lohse","year":"2016","journal-title":"Cancer Res."},{"key":"2025012305113520200_r25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3389\/fimmu.2019.00704","article-title":"Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG","volume":"10","author":"Brandsma","year":"2019","journal-title":"Front. Immunol."},{"key":"2025012305113520200_r26","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1053\/j.gastro.2009.06.047","article-title":"Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4","volume":"137","author":"van der Steen","year":"2009","journal-title":"Gastroenterology"},{"key":"2025012305113520200_r27","doi-asserted-by":"crossref","first-page":"112644","DOI":"10.1016\/j.jim.2019.112644","article-title":"Monitoring kinetics reveals critical parameters of IgA-dependent granulocyte-mediated anti-tumor cell cytotoxicity","volume":"473","author":"Zwick","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"2025012305113520200_r28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri1266","article-title":"Human antibody-Fc receptor interactions illuminated by crystal structures","volume":"4","author":"Woof","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"2025012305113520200_r29","doi-asserted-by":"crossref","first-page":"1165394","DOI":"10.3389\/fimmu.2023.1165394","article-title":"Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy","volume":"14","author":"Nihei","year":"2023","journal-title":"Front. Immunol."},{"key":"2025012305113520200_r30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1380-2933(98)00012-8","article-title":"Production and characterization of recombinant IgA","volume":"4","author":"Chintalacharuvu","year":"1999","journal-title":"Immunotechnology"},{"key":"2025012305113520200_r31","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.4049\/jimmunol.169.9.5072","article-title":"Cysteine residues required for the attachment of the light chain in human IgA2","volume":"169","author":"Chintalacharuvu","year":"2002","journal-title":"J. Immunol."},{"key":"2025012305113520200_r32","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jmb.2004.03.007","article-title":"Solution structure determination of monomeric human IgA2 by X-ray and neutron scattering, analytical ultracentrifugation and constrained modelling: a comparison with monomeric human IgA1","volume":"338","author":"Furtado","year":"2004","journal-title":"J. Mol. Biol."},{"key":"2025012305113520200_r33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.4049\/jimmunol.134.1.573","article-title":"A novel IgA protease from Clostridium sp. capable of cleaving IgA1 and IgA2 A2m(1) but not IgA2 A2m(2) allotype paraproteins","volume":"134","author":"Fujiyama","year":"1985","journal-title":"J. Immunol."},{"key":"2025012305113520200_r34","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.4049\/jimmunol.1003082","article-title":"Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing","volume":"186","author":"Lohse","year":"2011","journal-title":"J. Immunol."},{"key":"2025012305113520200_r35","doi-asserted-by":"crossref","first-page":"25139","DOI":"10.1074\/jbc.M112.353060","article-title":"Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages","volume":"287","author":"Lohse","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2025012305113520200_r36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/1535-7163.MCT-20-0173","article-title":"The HPV and p63 status in penile cancer are linked with the infiltration and therapeutic availability of neutrophils","volume":"20","author":"Bernhard","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"2025012305113520200_r37","doi-asserted-by":"crossref","first-page":"E207","DOI":"10.1002\/ijc.29112","article-title":"Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines","volume":"136","author":"Olthof","year":"2015","journal-title":"Int. J. Cancer"},{"key":"2025012305113520200_r38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2025012305113520200_r39","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.15252\/emmm.201404976","article-title":"The Hippo\/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression","volume":"7","author":"He","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"2025012305113520200_r40","doi-asserted-by":"crossref","first-page":"891511","DOI":"10.3389\/fonc.2022.891511","article-title":"The prominent role of the S100A8\/S100A9-CD147 axis in the progression of penile cancer","volume":"12","author":"Mohr","year":"2022","journal-title":"Front. Oncol."},{"key":"2025012305113520200_r41","doi-asserted-by":"crossref","first-page":"e00283","DOI":"10.1042\/BSR20150256","article-title":"How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity","volume":"36","author":"Grass","year":"2015","journal-title":"Biosci. Rep."},{"key":"2025012305113520200_r42","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.4049\/jimmunol.171.4.1707","article-title":"Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts","volume":"171","author":"Staffler","year":"2003","journal-title":"J. Immunol."},{"key":"2025012305113520200_r43","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/j.1582-4934.2010.01012.x","article-title":"Involvement of HAb18G\/CD147 in T cell activation and immunological synapse formation","volume":"14","author":"Hu","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"2025012305113520200_r44","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.molimm.2007.09.032","article-title":"LFA-1-mediated leukocyte adhesion regulated by interaction of CD43 with LFA-1 and CD147","volume":"45","author":"Khunkaewla","year":"2008","journal-title":"Mol. Immunol."},{"key":"2025012305113520200_r45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/biom10040541","article-title":"CD147 is a novel interaction partner of integrin \u03b1M\u03b22 mediating leukocyte and platelet adhesion","volume":"10","author":"Heinzmann","year":"2020","journal-title":"Biomolecules"},{"key":"2025012305113520200_r46","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.169.7.3831","article-title":"Mac-1 (CD11b\/CD18) as accessory molecule for Fc alpha R (CD89) binding of IgA","volume":"169","author":"Van Spriel","year":"2002","journal-title":"J. Immunol."},{"key":"2025012305113520200_r47","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V97.8.2478","article-title":"Mac-1 (CD11b\/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation","volume":"97","author":"Van Spriel","year":"2001","journal-title":"Blood"},{"key":"2025012305113520200_r48","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","article-title":"Neutrophils kill antibody-opsonized cancer cells by trogoptosis","volume":"23","author":"Matlung","year":"2018","journal-title":"Cell Rep."},{"key":"2025012305113520200_r49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/2326-6066.CIR-20-0491","article-title":"Kindlin3-dependent CD11b\/CD18-integrin activation is required for potentiation of neutrophil cytotoxicity by CD47-SIRP\u03b1 checkpoint disruption","volume":"9","author":"Bouti","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"2025012305113520200_r50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/35073095","article-title":"Cell control by membrane-cytoskeleton adhesion","volume":"2","author":"Sheetz","year":"2001","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"2025012305113520200_r51","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nature08908","article-title":"Cell mechanics and the cytoskeleton","volume":"463","author":"Fletcher","year":"2010","journal-title":"Nature"},{"key":"2025012305113520200_r52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrm1549","article-title":"Focal adhesion kinase: in command and control of cell motility","volume":"6","author":"Mitra","year":"2005","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"2025012305113520200_r53","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.4049\/jimmunol.1202037","article-title":"Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies","volume":"189","author":"Derer","year":"2012","journal-title":"J. Immunol."},{"key":"2025012305113520200_r54","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1038\/ncomms13354","article-title":"Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy","volume":"7","author":"Lee","year":"2016","journal-title":"Nat. Commun."},{"key":"2025012305113520200_r55","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1074\/jbc.M807529200","article-title":"The nonplanar secretory IgA2 and near planar secretory IgA1 solution structures rationalize their different mucosal immune responses","volume":"284","author":"Bonner","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2025012305113520200_r56","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4049\/jimmunol.180.2.1008","article-title":"Implications of the near-planar solution structure of human myeloma dimeric IgA1 for mucosal immunity and IgA nephropathy","volume":"180","author":"Bonner","year":"2008","journal-title":"J. Immunol."},{"key":"2025012305113520200_r57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41467-019-13992-8","article-title":"IgA subclasses have different effector functions associated with distinct glycosylation profiles","volume":"11","author":"Steffen","year":"2020","journal-title":"Nat. Commun."},{"key":"2025012305113520200_r58","doi-asserted-by":"crossref","first-page":"E8882","DOI":"10.1073\/pnas.1807478115","article-title":"Fc\u03b1RI binding at the IgA1 CH2-CH3 interface induces long-range conformational changes that are transmitted to the hinge region","volume":"115","author":"Posgai","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2025012305113520200_r59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrm1548","article-title":"ADAMs: key components in EGFR signalling and development","volume":"6","author":"Blobel","year":"2005","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"2025012305113520200_r60","doi-asserted-by":"crossref","first-page":"e12702","DOI":"10.1371\/journal.pone.0012702","article-title":"Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma","volume":"5","author":"Hatakeyama","year":"2010","journal-title":"PLoS One"},{"key":"2025012305113520200_r61","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/cancers12040893","article-title":"Mechanisms of resistance to NK cell immunotherapy","volume":"12","author":"Sordo-Bahamonde","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025012305113520200_r62","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1111\/febs.13414","article-title":"Soluble extracellular matrix metalloproteinase inducer (EMMPRIN, EMN) regulates cancer-related cellular functions by homotypic interactions with surface CD147","volume":"282","author":"Knutti","year":"2015","journal-title":"FEBS J."},{"key":"2025012305113520200_r63","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-021-00677-2","article-title":"CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression","volume":"6","author":"Cui","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"2025012305113520200_r64","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/j.csbj.2023.04.002","article-title":"Comprehensive analysis of glycoprotein VI-mediated platelet activation signaling pathway for predicting pan-cancer survival and response to anti-PD-1 immunotherapy","volume":"21","author":"Chen","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"2025012305113520200_r65","doi-asserted-by":"crossref","first-page":"32804","DOI":"10.1038\/srep32804","article-title":"CD147\/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis","volume":"6","author":"Xin","year":"2016","journal-title":"Sci. Rep."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/213\/2\/148\/61206098\/ji2300544.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/213\/2\/148\/61206098\/ji2300544.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:12:08Z","timestamp":1737609128000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/213\/2\/148\/7925894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,7,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2300544","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,24]]}}}